Aarti Pharmalabs Ltd
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]
- Market Cap ₹ 5,538 Cr.
- Current Price ₹ 611
- High / Low ₹ 653 / 320
- Stock P/E 27.6
- Book Value ₹ 179
- Dividend Yield 0.33 %
- ROCE 16.4 %
- ROE 13.1 %
- Face Value ₹ 5.00
Pros
Cons
- Company has a low return on equity of 13.6% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
0 | 941 | 1,511 | 1,502 | |
0 | 761 | 1,203 | 1,156 | |
Operating Profit | 0 | 180 | 309 | 346 |
OPM % | 19% | 20% | 23% | |
0 | 3 | 1 | 11 | |
Interest | 0 | 11 | 20 | 17 |
Depreciation | 0 | 37 | 56 | 66 |
Profit before tax | 0 | 134 | 233 | 275 |
Tax % | 20% | 26% | 27% | |
0 | 107 | 172 | 201 | |
EPS in Rs | 18.95 | 22.14 | ||
Dividend Payout % | 0% | 11% | 14% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 17% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 65% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 14% |
Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Equity Capital | 0 | 0 | 45 | 45 |
Reserves | -0 | 1,284 | 1,393 | 1,576 |
0 | 327 | 208 | 272 | |
0 | 215 | 317 | 404 | |
Total Liabilities | 0 | 1,827 | 1,963 | 2,297 |
0 | 701 | 848 | 1,012 | |
CWIP | 0 | 187 | 102 | 78 |
Investments | 0 | 40 | 43 | 62 |
0 | 898 | 970 | 1,145 | |
Total Assets | 0 | 1,827 | 1,963 | 2,297 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
0 | -65 | 229 | 184 | |
0 | -134 | -116 | -184 | |
0 | 255 | -157 | 4 | |
Net Cash Flow | 0 | 56 | -43 | 4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 118 | 87 | 109 | |
Inventory Days | 359 | 280 | 283 | |
Days Payable | 106 | 114 | 124 | |
Cash Conversion Cycle | 371 | 253 | 268 | |
Working Capital Days | 263 | 168 | 202 | |
ROCE % | 18% | 16% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Credit Rating
26 Jun - Reaffirmation of Credit Rating for long-term bank loan facilities
- Closure of Trading Window 26 Jun
-
Announcement Under Regulation 30 Of SEBI LODR, 2015
31 May - Closure of manufacturing activities at the Company''s Dombivli Plant
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
23 May - Secretarial Compliance Report for the Financial Year ended March 31, 2024
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
17 May - Transcript of Q4 FY 24 Earnings Conference Call
Annual reports
Concalls
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
Business Overview:[1]
Aarti Pharmalabs Limited (APL) formerly known as Aarti Organics was established in 1984 as a WOS of Aarti Industries Limited. Got demerged in Oct,22 into a separately listed entity.
Co. is an internationally recognized manufacturer of generic API & Intermediates, Xanthine derivatives and offers CDMO/CMO services. Company has 6 manufacturing plants and 3 R&D centres.